Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

GLP-1 agonists remain out of reach for many due to high costs, leading some patients to turn to unsafe compounded versions ...

Automated three-dimensional total-body photography improves the efficiency of positive malignant biopsies and reduces unnecessary biopsies of skin lesions, a study showed.

While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...

British investment firm SV Health Investors has secured $250 million to go toward the development of first-in-class ...

Eli Lilly says it is a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes that activates both GIP and ...

Eli Lilly (NYSE: LLY) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

The 2.5 mg vial and 5 mg vial will be available at Rs 3,500 and Rs 4,375, respectively. A spokesperson said as Mounjaro ...

Eli Lilly’s Mounjaro has launched in India. Approved by CDSCO, it promises significant weight loss and blood sugar control. However, concerns remain over certain side effects.

The popular anti-obesity drug Mounjaro has finally been launched in India. The development comes after Eli Lilly received ...

At STAT's Breakthrough Summit East, the CEOs of Ro and Included Health said the the U.S. health care system poses obstacles ...